-
Mark JD. Acupuncture and pediatric asthma. Altern Med Alert 2003;6(12):136-139.
-
Coenzyme Q10. Altern Med Alert 2003;6(suppl 12):S1-S2.
-
Greenfield RH. Pollution and cerebrovascular disease. Altern Med Alert 2003;6(12):143-144.
-
Lutz R. Capsaicin and neuropathic pain. Altern Med Alert 2003;6(12):139-143.
-
O'Mathuna DP. Coenzyme Q10 for neurological diseases. Altern Med Alert 2003;6(12):133-136.
-
Reversing Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) is a prospective, randomized, controlled trial assessing the effectiveness of an intensive or aggressive lipid-lowering approach
(atorvastatin 80 mg) to a moderate one (pravastatin 40 mg).
-
In the Valsartan in Acute Myocardial Infarction Trial (VALIANT) the angiotensin II receptor blocker (ARB) valsartan (V) was evaluated in 14,703 high-risk acute MI patients to determine its efficacy and safety
profile compared to the ACE inhibitor captopril (C).
-
Dr. Joseph Ornato presented the Public Access Defibrillation (PAD) study, which evaluated the efficacy of out-of-hospital cardiac arrest treatment by cardiopulmonary resuscitation (CPR) alone vs CPR plus
use of an automatic external defibrillator (AED) performed by trained laypersons.
-
Studies of selected patients with ischemic cardiomyopathy have shown improved survival with the use of prophylactic implantable cardioverter
defibrillators (ICD). Thus, DEFibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) was designed to test the survival benefit of ICDs in patients with heart failure but without coronary artery disease.
-
The efficacy and safety study of oral direct thrombin Inhibitor Ximelagatran Compared with Dose-Adjusted Warfarin in the Prevention of Stroke and Systemic Embolic Events in Patients with Atrial Fibrillation (SPORTIF V) was presented by Dr. Jonathan Halperin.